AI program predicting protein structures, by DeepMind
Moonshot has released Kimi K3, an open-weight model that independent tests say matches frontier performance and has prompted investor selling in chip stocks. Tech figures and regulators are trading accusations about distillation and national security, while industry voices argue the alarm is exaggerated.
Google has reorganised its AI leadership: Demis Hassabis has stepped back from day-to-day running of DeepMind to become its chair and Alphabet chief scientist, and Koray Kavukcuoglu has been promoted to senior vice-president to run Google DeepMind. Several senior engineers, including Jeff Dean and Sanjay Ghemawat, have left to launch a new startup; Alphabet shares have fallen.
Researchers at Stanford and the Arc Institute have used generative genome models to design and synthesise bacteriophage genomes; 16 of the lab-made viruses proved viable and a cocktail of them rapidly killed E. coli strains resistant to natural phages. Experts have warned the work has raised urgent biosafety and biosecurity questions about AI-designed genomes.
A wave of senior leadership departures across major AI labs has intensified as firms recalibrate leadership ahead of anticipated IPOs and major infrastructure overhauls. OpenAI and Anthropic are among those restructuring as executives exit and reassignments take place, with a broader industry shift toward aligning compute strategies with growth goals.
Senior researchers and executives have warned that frontier artificial intelligence could escape human control and pose existential risks. Anthropic staffers and former employees have raised the possibility of human extinction; Anthropic and OpenAI have proposed independent evaluators and coordination to pause development while regulators and politicians debate responses.
Arm Holdings chief executive Rene Haas says AI could one day help cure cancer, but the path is constrained by chip shortages and a demand surge for AI data centres. Multiple outlets report Haas’s remarks, framing a broaderAI-driven push in healthcare and manufacturing, while flagging supply constraints and broader market excitement.
Anthropic has expanded its biology lab in San Francisco and bought Coefficient Bio to explore AI-assisted biotech. Leaders say real-life lab work is essential to testing AI-driven theories, while the company faces pushback from customers and industry observers over potential competition and safety concerns.